876
Participants
Start Date
June 30, 2015
Primary Completion Date
January 31, 2020
Study Completion Date
February 29, 2020
HSCT from MSD
HSCT from MSD is the first choice for the patients who have HLA-matched sibling donors.
HSCT from MUD
HSCT from MUD is the second choice for the patients who don't have HLA-matched sibling donors but have HLA-matched unrelated donors.
HSCT from HRD
HSCT from HRD is the choice for the patients who have neither HLA-matched sibling donors nor HLA-matched unrelated donors.
Cyclosporin A
CsA is used in all the patients for GVHD prophylaxis.
Methotrexate
MTX is used in all the patients for GVHD prophylaxis.
Antithymocyte globulin
ATG is used in the patients receiving HSCT from MUD and HRD for GVHD prophylaxis.In MUD group,total ATG doses is 7 mg/kg;In HRD group,total ATG doses is 7.5 or 10 mg/kg.
Mycophenolate mofetil
MMF is used in the patients receiving HSCT from MSD and HRD for GVHD prophylaxis.
Department of Hematology,Nanfang Hospital, Southern Medical University, Guangzhou
Guangdong Provincial People's Hospital
OTHER
Third Affiliated Hospital, Sun Yat-Sen University
OTHER
Guangzhou General Hospital of Guangzhou Military Command
OTHER
Guangzhou First People's Hospital
OTHER
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
OTHER
Zhujiang Hospital
OTHER
Tongji Hospital
OTHER
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
OTHER
Fujian Medical University Union Hospital
OTHER
First Affiliated Hospital of Guangxi Medical University
OTHER
Xiangya Hospital of Central South University
OTHER
Nanfang Hospital, Southern Medical University
OTHER